Clinical Trial Update: Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial (AVENIR) is evaluating low-dose arginine-vasopressin supplementation to prevent or reduce acute kidney injury following liver transplan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• Arginine-vasopressin (arginine vasopressin)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Acute Kidney Injury Post Liver Transplantation | Phase 3 | Status: RECRUITING